ZA201000129B - Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted - Google Patents

Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Info

Publication number
ZA201000129B
ZA201000129B ZA2010/00129A ZA201000129A ZA201000129B ZA 201000129 B ZA201000129 B ZA 201000129B ZA 2010/00129 A ZA2010/00129 A ZA 2010/00129A ZA 201000129 A ZA201000129 A ZA 201000129A ZA 201000129 B ZA201000129 B ZA 201000129B
Authority
ZA
South Africa
Prior art keywords
kncq
disrupted
conditions
potassium channel
treating disorders
Prior art date
Application number
ZA2010/00129A
Other languages
English (en)
Inventor
Klaus Peter Hertel
Henriette Husum Bak-Jensen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201000129(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ZA201000129B publication Critical patent/ZA201000129B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2010/00129A 2007-08-01 2010-01-07 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted ZA201000129B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200701110 2007-08-01
PCT/DK2008/050191 WO2009015667A1 (en) 2007-08-01 2008-07-31 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Publications (1)

Publication Number Publication Date
ZA201000129B true ZA201000129B (en) 2011-04-28

Family

ID=39810209

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/00129A ZA201000129B (en) 2007-08-01 2010-01-07 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Country Status (17)

Country Link
US (1) US20100256145A1 (enExample)
EP (1) EP2185149A1 (enExample)
JP (1) JP2011513196A (enExample)
KR (1) KR20100050502A (enExample)
CN (1) CN101790374A (enExample)
AR (1) AR070513A1 (enExample)
AU (1) AU2008281112A1 (enExample)
BR (1) BRPI0814180A2 (enExample)
CA (1) CA2694887A1 (enExample)
CL (1) CL2008002273A1 (enExample)
EA (1) EA201070189A1 (enExample)
MX (1) MX2010001171A (enExample)
NZ (1) NZ582942A (enExample)
TW (1) TW200920350A (enExample)
UA (1) UA97847C2 (enExample)
WO (1) WO2009015667A1 (enExample)
ZA (1) ZA201000129B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
KR20130115393A (ko) * 2008-02-21 2013-10-21 미쓰비시 타나베 파마 코퍼레이션 경구 투여용 고형 제제
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2010105189A1 (en) * 2009-03-12 2010-09-16 The Johns Hopkins University Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age
US20120059037A1 (en) 2009-03-17 2012-03-08 Neurosearch A/S Substituted pyridine derivatives and their medical use
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
BRPI1014545A2 (pt) * 2009-05-29 2016-04-05 Astellas Pharma Inc composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
JP5763758B2 (ja) 2010-07-08 2015-08-12 ファイザー・インク Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9321750B2 (en) * 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
EA029826B1 (ru) 2013-12-02 2018-05-31 Кемосентрикс, Инк. Соединения против ccr6
JP6217866B2 (ja) * 2014-10-24 2017-10-25 小野薬品工業株式会社 Ｋｃｎｑ２〜５チャネル活性化剤
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
MX2018015251A (es) * 2016-06-10 2019-04-25 Scifluor Life Sciences Inc Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado.
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
JP7121144B2 (ja) 2018-02-20 2022-08-17 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
TWI788325B (zh) * 2018-02-21 2023-01-01 丹麥商Ｈ 朗德貝克公司 作為Ｋｖ７鉀通道開放劑的醇衍生物
WO2019203951A1 (en) * 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN108707087B (zh) * 2018-06-29 2020-10-16 河北医科大学 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途
CN108863893A (zh) * 2018-07-09 2018-11-23 湖南博隽生物医药有限公司 二氢吲哚类衍生物及其在药物中的应用
EP4360632B1 (en) 2019-01-15 2025-10-29 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CN119490430A (zh) 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
JP7720829B2 (ja) 2019-08-02 2025-08-08 ハー・ルンドベック・アクチエゼルスカベット Ｋｖ７カリウムチャネル開口薬としてのアルコール誘導体
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CN114667146A (zh) 2019-11-08 2022-06-24 泽农医药公司 治疗抑郁症的方法
KR102643653B1 (ko) * 2020-11-13 2024-03-06 기초과학연구원 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
PE20231815A1 (es) * 2021-02-09 2023-11-16 Xenon Pharmaceuticals Inc Abridor de canales de potasio controlado por voltaje para uso en el tratamiento de la anhedonia
CN116535353A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的酰胺类化合物及其制备和应用
CN118026880A (zh) * 2022-11-11 2024-05-14 华东师范大学 芳基酰胺化合物、包含其的药物组合物及其用途
TW202521516A (zh) * 2023-08-17 2025-06-01 加拿大商再諾製藥公司 氮雜環庚烷及吡咯啶化合物及其用途
WO2026012444A1 (zh) * 2024-07-10 2026-01-15 宜昌人福药业有限责任公司 通道小分子激活剂及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (enExample) * 1990-07-14 1993-08-14 Asta Medica Ag
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
JP2003506387A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
MXPA03007397A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
EP1392644A1 (en) * 2001-05-31 2004-03-03 Bristol-Myers Squibb Company Cinnamide derivatives as kcnq potassium channel modulators
EP1581516A4 (en) * 2002-11-22 2007-10-17 Bristol Myers Squibb Co BENZYLAMIDE 3-HETEROCYCLIC DERIVATIVES AS POTASIC CHANNEL OPENING AGENTS
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
WO2004058739A1 (en) * 2002-12-27 2004-07-15 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
EP1603858A2 (en) * 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
BRPI0408205A (pt) * 2003-03-14 2006-02-14 Lundbeck & Co As H derivado de anilina substituìdo, composição farmacêutica, e, uso de uma composição farmacêutica
EP1613303A1 (en) * 2003-03-21 2006-01-11 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
AU2004233941A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
CA2599890C (en) * 2005-03-03 2011-05-03 H. Lundbeck A/S Substituted pyridine derivatives
AU2006322461A1 (en) * 2005-09-09 2007-06-14 H. Lundbeck A/S Pyrimidine derivatives and their use as KCNQ potassium channels openers
US20090118285A1 (en) * 2006-02-07 2009-05-07 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
WO2007128462A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms

Also Published As

Publication number Publication date
EA201070189A1 (ru) 2010-08-30
AU2008281112A1 (en) 2009-02-05
WO2009015667A1 (en) 2009-02-05
UA97847C2 (ru) 2012-03-26
BRPI0814180A2 (pt) 2015-01-27
EP2185149A1 (en) 2010-05-19
KR20100050502A (ko) 2010-05-13
CN101790374A (zh) 2010-07-28
JP2011513196A (ja) 2011-04-28
CA2694887A1 (en) 2009-02-05
US20100256145A1 (en) 2010-10-07
NZ582942A (en) 2011-09-30
MX2010001171A (es) 2010-03-01
AR070513A1 (es) 2010-04-14
TW200920350A (en) 2009-05-16
CL2008002273A1 (es) 2009-07-17

Similar Documents

Publication Publication Date Title
MX2010001171A (es) Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sistema dopaminergico.
IL260117A (en) Use of placental cells to treat diseases, syndromes or conditions of the lungs
IL204785A0 (en) Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
IL222695A0 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
IL206160A0 (en) Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
MX2010007490A (es) Preparacion de derivados de sulfamida.
BRPI1014994A2 (pt) 2,4-diamino pirimidinas para o tratamento de doenças caracterizadas por proliferação excessiva ou anormal de células
LT2427193T (lt) Pde7 inhibitoriaus panaudojimas judėjimo sutrikimų gydymui
EP2437725A4 (en) TOPICAL MICROEMULSIONS FOR THE TREATMENT OF RHEUMATIC SUFFERINGS
IL215584A0 (en) Methods for preventing and/or treating degenerative disorders of the central nervous system
LT2229369T (lt) 6,7-dialkoksi-chinazolino dariniai, tinkami panaudoti su vėžiu susijusių susirgimų gydymui
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
IL192745A0 (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
ZA201001705B (en) Azithromycin for treatment of skin disorders
IL215990A0 (en) Phosphotetrahydfropyran compounds for the treatment of wounds and fibrotic disorders
IL202091A0 (en) Methods of treating cognitive disorders by inhibition of gpr12
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
ZA201204391B (en) Compounds for the treatment of neurologic disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
WO2011084523A3 (en) Ulk1 compositions, inhibitors, screening and methods of use
EP2387565A4 (en) 2,4-PYRIMIDINDIAMIN COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
AU2009223851A8 (en) Methods of treating hyperacidic disorders